

4-27-05

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/050,231

Filing Date 01/16/2002

First Named Inventor William H. Hildebrand et al.

Art Unit 1644 (Conf. No. 8620)

Examiner Name F. VanderVegt

Attorney Docket Number 6680.036

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation of POA, Change of Correspondence Address	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	1. Transmittal (1 page); 2. Fee Transmittal (1 page); 3. Credit Card Payment Form (1 page); 4. Second Supplemental Information Disclosure Statement (3 pages); 5. Second Supplemental Form PTO-1449 (2 pages); 6. Copies of cited material; and 7. Return Receipt Postcard.	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	DUNLAP, CODDING & ROGERS, P.C.	
Signature		
Printed name	Douglas J. Sorocco	
Date	4-26-05	Reg. No. Reg. No. 43,145

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. *** SENT BY EXPRESS MAIL NO. EV368016506US, DATED 04/26/2005***

Signature

Typed or printed name

Douglas J. Sorocco

Date

4-26-05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

APR 26 2005

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

Complete if Known

Application Number	10/050,231
Filing Date	01/16/2002
First Named Inventor	William H. Hildebrand et al.
Examiner Name	F. VanderVegt
Art Unit	1644 (Conf. No. 8620)
Attorney Docket No.	6680.036

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____
 Deposit Account Deposit Account Number: _____ Deposit Account Name: _____

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee
 Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments
 under 37 CFR 1.16 and 1.17

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	
Utility	300	150	500	250	200	100	_____
Design	200	100	100	50	130	65	_____
Plant	200	100	300	150	160	80	_____
Reissue	300	150	500	250	600	300	_____
Provisional	200	100	0	0	0	0	_____

2. EXCESS CLAIM FEES

Fee Description

Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent

Small Entity

Fee (\$) Fee (\$)

50 25

Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent

200 100

Multiple dependent claims

360 180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
- 20 or HP =	x 0.00	= 0.00	

Multiple Dependent Claims	
Fee (\$)	Fee Paid (\$)
0	0.00

HP = highest number of total claims paid for, if greater than 20

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
- 3 or HP =	x 0.00	= 0.00	

HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	0	/ 50 = (round up to a whole number)	x	= 0.00

Fees Paid (\$)

0.00

180.00

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: Second Supplemental Information Disclosure Statement

SUBMITTED BY

Signature	Registration No. (Attorney/Agent)	43,145	Telephone	405-607-8600
Name (Print/Type)	Douglas J. Sorocco Date 4-26-05			

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



EXPRESS MAIL NO.: EV368016506US

Deposited On: April 26, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/050,231

Confirmation No.: 8620

Applicant: William H. Hildebrand and Heather D. Hickman

Filed: 01/16/2002

TC/AU: 1644

Examiner: F. VanderVegt

Title: SOLUBLE MHC ARTIFICIAL ANTIGEN PRESENTING CELLS

Docket No.: 6680.036

Customer No.: 30589

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**List of Sections Forming Part of This
Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. FORM PTO-1449 (Modified)
3. Copies of Listed Information Items Accompanying this Statement
4. Identification of Person(s) Making this Information Disclosure Statement

04/26/2005 WARDER1 000000030 10050931
01 FC1806
180.00 0P

Section 1. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 2. Form PTO-1449 (Modified)

A completed Form 1449 (Modified) is attached hereto.

Section 3. Copies of Listed Information Items Accompanying this Statement

Legible copies of all items listed in Form PTO-1449 (Modified) accompany this information disclosure statement.

Section 4. Identification of Person(s) Making this INFORMATION DISCLOSURE STATEMENT

The person making this statement is the attorney who signs below on the basis of the information:

supplied by the inventor(s)

supplied by an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c)).

in the attorney's file

Respectfully submitted,



Douglas J. Sorocco, Reg. No. 43,145
DUNLAP, CODDING & ROGERS, P.C.
P.O. Box 16370
Oklahoma City, Oklahoma 73113
Telephone: (405) 607-8600
Facsimile: (405) 607-8686

Attorney for Applicant

APR 26 2005

Page 1 of 2Express Mail: 10368016506US
Date Deposited: APR 26 2005

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Second Supplemental IDS)**

(use as many sheets as necessary)

Complete if Known	
Application Number	10/050,231
Filing Date	01/16/2002
First Named Inventor	William H. Hildebrand et al.
Group Art Unit	1644
Examiner Name	F. VanderVegt
Attorney Docket Number	6680.036


U. S. PATENT DOCUMENTS

EXAM INIT.	Cite No. 1	U.S. PATENT NUMBER Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5830995		Shoyab et al.	11/03/1998	
	AB	6232445		Rhode et al.	05/2001	

FOREIGN PATENT DOCUMENTS

EXAM INIT.	Cite No. 1	Foreign Patent Document		Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office 3	Number 4					

U.S. and Foreign:¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



EXAM INIT.		PATENT DOCUMENTS
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	AA	"GENERIC LIPOSOME REAGENT FOR IMMUNOASSAYS", Plant et al., Analytical Biochemistry, Vol. 176, Issue 2, pages 420-426 (1989).
	AB	"DISSOCIATION OF THE PEPTIDE-MHC CLASS I COMPLEX LIMITS THE BINDING RATE OF EXOGENOUS PEPTIDE", Ojcius et al., Journal of Immunology, vol. 151, no. 11, pages 6020-6026 (1993).
	AC	"DISSOCIATION OF THE PEPTIDE/MHC CLASS I COMPLEX: pH DEPENDENCE AND EFFECT OF ENDOGENOUS PEPTIDES ON THE ACTIVATION ENERGY, Ojcius et al., Biochemical and Biophysical Research Communications, vol. 197, no. 3, pages 1216-1222 (1993).
	AD	"ROLE OF HLA-A MOTIFS IN IDENTIFICATION OF POTENTIAL CTL EPITOPE IN HUMAN PAPILLOMAVIRUS TYPE 16 E6 AND E7 PROTEINS", Kast et al., Journal of Immunology, vol. 152, no. 8, pages 3904-3912 (1994).
	AE	"THE ACCESSIBILITY OF PEPTIDES BOUND TO THE MOUSE MHC CLASS II MOLECULE IE-d STUDIED BY FLUORESCENCE", Federation of European Biochemical Societies Letters, vol. 342, no. 3, pages 230-234 (1994).
	AF	"A NEW MURINE LYMPHOCYTOTOXIC MONOCLONAL ANTIBODY RECOGNIZING HLA-A2, -A28 AND -A9", Mizuno et al., Tissue Antigens, 48:224-227 (1996).
	AG	"THE USE OF MAGNETIC BEADS COATED WITH SOLUBLE HLA CLASS I OR CLASS II PROTEINS IN ANTIBODY SCREENING AND FOR SPECIFICITY DETERMINATION OF DONOR-REACTIVE ANTIBODIES", Sumitran-Karuppan et al., Transplantation, 61(10):1539-1546 (1996).
	AH	"ANTIBODY SCREENING BY ENZYME-LINKED IMMUNOSORBENT ASSAY USING POOLED SOLUBLE HLA IN RENAL TRANSPLANT CANDIDATES", Zaer et al., Transplantation, 63(1):48-51 (1997).
	AI	"IN VITRO INDUCTION OF SPECIFIC CYTOTOXIC T LYMPHOCYTES USING RECOMBINANT SINGLE-CHAIN MHC CLASS I/PEPTIDE COMPLEXES", Lone et al., Journal of Immunotherapy, 21(4):283-294 (1998).
	AJ	"A MUTANT HUMAN B ₂ -MICROGLOBULIN CAN BE USED TO GENERATE DIVERSE MULTIMERIC CLASS I PEPTIDE COMPLEXES AS SPECIFIC PROBES FOR T CELL RECEPTORS", Walter et al., Journal of Immunological Methods 214:41-50 (1998).
Non Patent Documents: ¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.		
Examiner Signature:		Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant. **Place of Publication refers to name of publication in which the information was published.		